BRIEF-Quest Diagnostics Q3 Adjusted EPS USD 3 Vs. IBES Estimate USD 2.86
Reuters2026/10/22 10:47Oct 22 (Reuters) - Quest Diagnostics Q3 net income USD 312 million.
- Q3 revenue USD 3,097 million vs. IBES estimate USD 3,046 million
- Q3 EPS USD 2.78
- outlook FY EPS USD 10.21-10.31
- outlook FY adjusted EPS USD 11.25-11.35 vs. IBES estimate USD 11.2
- outlook FY revenue USD 12,065-12,105 million vs. IBES estimate USD 12,001 million
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
